KALV
- KalVista Pharmaceuticals, Inc.
()
Overview
Company Summary
KalVista Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapeutics for diseases with significant unmet medical needs. The company specializes in the field of plasma kallikrein inhibition, which plays a crucial role in various diseases.
KalVista's primary area of interest is hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in different body parts. The company has developed a portfolio of small molecule drug candidates known as oral plasma kallikrein inhibitors. These inhibitors target and block the activity of plasma kallikrein, an enzyme involved in the production of bradykinin, a mediator of inflammation and the primary culprit in HAE attacks.
By inhibiting plasma kallikrein, KalVista's drug candidates aim to reduce the excessive production of bradykinin, thereby preventing or reducing the severity of HAE attacks. The oral formulation of their drugs offers a more convenient and patient-friendly alternative to existing injectable treatments for HAE.
Apart from HAE, KalVista is also exploring the potential of their plasma kallikrein inhibitors in other indications, such as diabetic macular edema (DME) and other retinal diseases. In DME, excess vascular leakage leads to fluid accumulation in the macula, causing vision impairment. KalVista's inhibitors may help reduce this leakage and offer a new treatment option for patients with DME.
Through their research and development efforts, KalVista Pharmaceuticals aims to address the substantial unmet medical needs in these disease areas and improve the lives of patients. They work closely with clinical experts, regulatory authorities, and strategic partners to advance their drug candidates from preclinical stages through clinical trials and ultimately towards commercialization.